688553 匯宇製藥
按盤價 
17.460 -0.510 (-2.838%) | 2025/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 741,750 | -12.92% | 1,094,382 | 927,075 | 1,493,268 | 1,823,733 | |
| 減：營業總成本 | 685,551 | -7.54% | 1,006,585 | 873,712 | 1,304,312 | 1,382,450 | |
| 其中:營業成本 | 144,712 | 0.83% | 181,511 | 130,447 | 176,182 | 157,299 | |
| 財務費用 | (32,548) | 137.66% | (22,120) | (41,802) | (46,899) | (4,955) | |
| 資產減值損失 | (1,468) | -84.72% | (14,814) | (2,307) | (3,933) | (2,892) | |
| 公允價值變動收益 | (160,999) | -239.39% | 239,856 | 6,440 | 2,327 | 6,156 | |
| 投資收益 | 3,332 | -78.32% | 13,815 | 34,183 | 42,894 | 12,845 | |
| 其中：對聯營企業和合營企業的投資收益 | 326 | -49.68% | (2,687) | 307 | 1,471 | 1,016 | |
| 營業利潤 | (77,309) | -131.63% | 348,432 | 124,368 | 235,448 | 478,755 | |
| 利潤總額 | (76,285) | -130.51% | 349,699 | 132,154 | 238,391 | 477,700 | |
| 減：所得稅費用 | (21,215) | -172.44% | 33,802 | (7,180) | (10,599) | 31,841 | |
| 淨利潤 | (55,070) | -124.94% | 315,897 | 139,335 | 248,991 | 445,859 | |
| 減：非控股權益 | (4,265) | -35.25% | (9,493) | (451) | -- | -- | |
| 股東淨利潤 | (50,805) | -122.35% | 325,390 | 139,786 | 248,991 | 445,859 | |
市場價值指標 | |||||||
| 每股收益 (元) * | -0.120 | -122.22% | 0.770 | 0.330 | 0.590 | 1.200 | |
| 每股派息 (元) * | -- | -- | 0.463 | 0.213 | 0.235 | 0.211 | |
| 每股淨資產 (元) * | 8.808 | -3.84% | 9.393 | 8.901 | 8.777 | 8.400 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 17/03/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
